AP
BIIB icon

Alydar Partners’s Biogen BIIB Stock Holding History

Alydar Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-35,000
Closed -$9.79M – 105
2013
Q4 		$9.79M Buy
+35,000
New +$9.05M 0.99% 34
2013
Q3 		– Sell
-120,000
Closed -$25.8M – 111
2013
Q2 		$25.8M Buy
+120,000
New +$25.6M 1.39% 25

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alydar Partners's BIIB Position: Q1 2014 in Review

Alydar Partners sold out of Biogen (BIIB) in Q1 2014, closing a stake of 35,000 shares — an estimated $9.79M sold.

Alydar Partners first reported a position in BIIB in Q2 2013 and held it in 2 quarters. The position peaked at $25.8M in Q2 2013. 776 funds tracked by Wall St. Rank hold BIIB as of Q1 2014.

  • Alydar Partners reported no remaining Biogen position as of Q1 2014 after selling out during the quarter.
  • Alydar Partners sold 35,000 Biogen shares in Q1 2014, an estimated $9.79M.
  • Alydar Partners first reported a position in Biogen in Q2 2013 and held it in 2 quarters.
  • Alydar Partners's Biogen position peaked at $25.8M in Q2 2013.
  • 776 funds tracked by Wall St. Rank held Biogen as of Q1 2014.

Based on Alydar Partners's 13F filing for Q1 2014, filed 15 May 2014.